Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma

L.L. Chen\textsuperscript{1,2}, Y. Shen\textsuperscript{3}, J.B. Zhang\textsuperscript{4}, S. Wang\textsuperscript{5}, T. Jiang\textsuperscript{6}, M.Q. Zheng\textsuperscript{6}, Z.J. Zheng\textsuperscript{7} and C.X. Chen\textsuperscript{1}

\textsuperscript{1}Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China
\textsuperscript{2}Department of Gastroenterology, The First People’s Hospital of Wenling, Wenling, China
\textsuperscript{3}Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China
\textsuperscript{4}Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
\textsuperscript{5}Department of Cardiology, The First People’s Hospital of Wenling, Wenling, China
\textsuperscript{6}Central Laboratory, The First People’s Hospital of Wenling, Wenling, China
\textsuperscript{7}Department of Hepatobiliary Surgery, The First People’s Hospital of Wenling, Wenling, China

Corresponding authors: Z.J. Zheng / C.X. Chen
E-mail: zhengzhijianz@163.com / chunxiachen66@sina.com

Received April 25, 2016
Accepted August 1, 2016
Published October 5, 2016
DOI http://dx.doi.org/10.4238/gmr.15048723

Copyright © 2016 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-SA) 4.0 License.

**ABSTRACT.** Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. MicroRNA-34 (miR-34) gene plays a key role in altering the apoptotic cycle and pathways of downstream
cells, and therefore influences carcinogenesis. In this case-control study, we assessed the role of the pri-miR-34b/c rs4938723 polymorphism in HCC risk. The pri-miR-34b/c polymorphic genotype was determined in 286 patients with HCC and 572 controls using polymerase chain reaction-restriction fragment length polymorphism. The male gender ($\chi^2 = 12.95$, $P < 0.001$), regular alcohol consumption ($\chi^2 = 16.81$, $P < 0.001$), and a family history of cancer ($\chi^2 = 11.88$, $P = 0.001$) were associated with HCC risk. However, the age ($t = 1.19$, $P = 0.12$) and tobacco smoking habit ($\chi^2 = 0.64$, $P = 0.42$) of HCC patients were comparable to those of the controls. The TC (adjusted OR = 1.46, 95%CI = 1.06-2.01) and CC (adjusted OR = 3.07, 95%CI = 1.77-5.34) genotypes of pri-miR-34b/c rs4938723 were correlated with a higher risk of HCC compared to the TT genotype. Moreover, the TC+CC genotype was correlated with an increased risk of HCC compared to the TT genotype (adjusted OR = 1.64, 95%CI = 1.21-2.22). In the recessive model, the CC genotype of pri-miR-34b/c rs4938723 was significantly correlated with an elevated risk of HCC compared to the TT+TC genotype (adjusted OR = 2.50, 95%CI = 1.49-4.22). Further large-scale and multi-center studies are required to confirm these results.

**Key words:** pri-miR-34b/c; Polymorphism; Hepatocellular carcinoma